| 1 |
Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health[CPH] study): a national cross-sectional study[J]. Lancet, 2018, 391(10131): 1706-1717.
|
| 2 |
Huang K, Yang T, Xu J, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study[J]. Lancet, 2019, 394(10196): 407-418.
|
| 3 |
Sulaiman I, Cushen B, Greene G, et al. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease [J]. Am J Respir Crit Care Med, 2017, 195(10): 1333-1343.
|
| 4 |
杨黎，杨丹榕，郭澄，等. 我院咳喘药学服务门诊项目的建设与实施效果[J]. 上海医药，2022, 43 (13): 9-12.
|
| 5 |
Augusta B, Dave S. The COPD assessment test (CAT) and depression：A longitudinal analysis during the COVID-19 pandemic[J]. Int J Chron Obstruct Pulmon Dis, 2023, 18: 1187-1195.
|
| 6 |
Claudia C, Raffaele C, Alberto N, et al. Comparability of asthma control test scores between self and physician-administered test[J] .Respir Med, 2020, 170: 106015.
|
| 7 |
Samy S. Guidelines for the pharmacologic treatment of COPD 2023: Canada versus GOLD[J]. COPD, 2024, 21(1): 2292613.
|
| 8 |
Nikhil R, Prawin K, Jagdish PG. Global initiative for asthma guidelines 2024: An update[J]. Indian Pediatr, 2024, 61(8): 781-786.
|
| 9 |
陈丹，刘国栋，刘煜，等. 咳喘医药联合门诊服务模式的实践与探索[J]. 药学实践与服务，2023, 41(11): 689-693.
|
| 10 |
Duffy SP, Criner GJ. Chronic obstructive pulmonary disease：evaluation and management[J]. Med Clin North Am, 2019, 103(3): 453-461.
|
| 11 |
Bao H, Jia G, Cong S, et al. Phenotype and management of chronic obstructive pulmonary disease patients in general population in China: a nationally crosssectional study[J]. NPJ Prim Care Respir Med, 2021, 31(1): 32.
|
| 12 |
郁件康，龚银华，郁文刘，等. PCCM咳喘药学服务门诊互联网＋智慧药学服务路径管理模式的构建与评价[J]. 医药导报，2023, 42(8): 1158-1165.
|
| 13 |
Ma XD, Wang Y, Chen YW, et al. Association between medication complexity and follow-up care attendance: insights from a retrospective multicenter cohort study across 1，223 Chinese hospitals[J]. Front Pharmacol, 2024, 15: 1448986.
|
| 14 |
高红利，李素仙，高伟祺，等． "互联网＋手机APP"的药学服务在COPD患者健康管理中的作用研究[J]. 药品评价，2019, 16(6): 3-6.
|
| 15 |
Global initiative for chronic obstructive pulmonary disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2021 report) [EB/0L]. [20211115].
|
| 16 |
Makhinova T, Johnson JA, Minhas-Sandhu JK, et al. Pharmacists′chronic disease management in chronic obstructive pulmonary disease: Effect on health services utilization[J]. J Manag Care Spec Pharm, 2023, 29(6): 671-679.
|
| 17 |
Jia X, Zhou S, Luo D, et al. Effect of pharmacist-led interventions on medication adherence and inhalation technique in adult patients with asthma or COPD: A systematic review and meta-analysis[J]. J Clin Pharm Ther, 2020, 45(5): 904-917.
|
| 18 |
Necyk C, Johnson JA, Tsuyuki RT, et al. Exploring the impact of pharmacist comprehensive annual care plans on perceived quality of chronic illness care by patients in Alberta, Canada[J]. Can Pharm J (Ott), 2021, 154(5): 331-341.
|
| 19 |
中国医学装备协会呼吸病学装备技术专业委员会，中华医学会呼吸病学分会慢性阻塞性肺疾病学组，广东省药学会. 稳定期慢性阻塞性肺疾病医药共管专家共识[J]. 中华结核和呼吸杂志，2022, 45(10): 980-987.
|
| 20 |
姜继锋，周元江，朱光贵，等. 咳喘慢性疾病患者门诊药学服务模式的建立与效果评估[J]. 中国当代医药，2023, 30(32): 122-125.
|
| 21 |
李亚芳，张晓华，韩祺炜，等. 咳喘药学门诊的构建及实践[J]. 中国现代应用药学，2023, 40(23): 3303-3307.
|
| 22 |
周海云，贡雪芃，刘东．《中国药学会咳喘药学服务门诊建设规范》解析[J]. 医药导报，2025, 44(3): 356-360.
|